On February 5th,2024 PM, Jiangsu Runan Pharmaceutical co., LTD. All staff gathered in Huai'an ShuXin hotel held 2023 annual work commendation meeting ,the annual ceremony is divided into annual  worl summary commendation , sign safety liability form and New Year art performance,  Company leadership and staff gathered, looking back 2023, looking forward to 2024.

After playing the national anthem, all the staff watched the 2023 summary video.

The picture scroll of time, always spread out in the struggle; wonderful chapter, always write in ceaseless struggle. Subsequently, General Manager Wu Tingzhao made A summary of the work of  year 2023  and the annual work plan of 2024. In this year, RunAn achieved good results, completed the 2 lines production of celecoxib,  production capacity doubled, the comprehensive cost decreased significantly; completed the application of pharmaceutical production license of Runan Pharmaceutical Company; carried out the establishment of "provincial health enterprise", and the enterprise was rated as "Grade A performance of key industries" for two consecutive years. And then General manager arranged the next yaear‘s main works.

Subsequently, General Manager announced Jiangsu Runan Pharmaceutical Co., Ltd. 2024 "Middle-levelManagement Personnel Position Employment Decision" and "Decision on the Position Employment of Supervisors".

Then, Chen Hongxi, director of EHS, and Zhu Wenjuan, manager of QA, made the 2023 work summary and 2024 work plan respectively, which made a comprehensive and objective summary of the work in 2023, and put forward the key points and direction of efforts for next year through careful sorting and sharing of shortcomings.

then, administrative Director Zhou Weijun read out the decision of 2023 advanced woker, quality, safety, advanced team, and Runan internal safety advanced individual commendation. General manager Wu Tingzhao presented the award to the advanced employees.

Advanced employee representatives spoke in turn, in order to encourage the company's employees to forge ahead and strive to be the first .

We can supplu the listed main API products: Gemcitabine hydrochloride, Celecoxib, bromhexine hydrochloride, Iguratimod ,Apremilast, Tofactinib Citrate ,Crisaborole, Urapidil Hydrochloride ,Sugammadex sodium , Garlicin, Dexmedetomidine Hydrochloride, Rocuronium bromide, Finerenone Sodium risedronate, etc.

We sincerely wish the company a prosperous performance in the coming year,fighting.